Partial remission with sintilimab monotherapy in a patient carrying a <em>CD274</em> amplification in refractory diffuse large B‑cell lymphoma: A case report

Zhang,Xian; Xu,Liye; Pan,Evenki; Sun,Xiuhua; Ding,Xiaolei

doi:10.3892/ol.2024.14423

Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B‑cell lymphoma: A case report

Authors:
- Xian Zhang
- Liye Xu
- Evenki Pan
- Xiuhua Sun
- Xiaolei Ding
View Affiliations

Affiliations: Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China, Department of Medical Services, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu 210031, P.R. China
Published online on: April 30, 2024 https://doi.org/10.3892/ol.2024.14423
Article Number: 289
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse large B‑cell lymphoma (DLBCL) is a heterogeneous disease with varying characteristics, in terms of genomic variation, cell morphology and clinical presentation. At present, only ~66% of patients are cured with initial treatment and those with refractory DLBCL exhibit a poor prognosis. Thus, further investigations into novel effective treatment options for DLBCL are required. The present study reports the case of a patient resistant to multiple therapies, including rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑CHOP) plus enzastaurin (trial no. CTR20171560), GemOx plus lenalidomide and selinexor (trial no. ATG‑010‑DLBCL‑001). The patient harbored a CD274 amplification, as identified via next‑generation sequencing (NGS), and exhibited a high programmed death‑ligand 1 Tumor Proportion Score of up to 95%. Consequently, the patient was treated with sintilimab monotherapy and the response lasted for 12 months of follow‑up without major immune‑related adverse events. This case highlights the role of NGS technology in selecting treatment options for refractory DLBCL. Furthermore, the results of the present study suggest that sintilimab may have potential in the treatment of patients with refractory DLBCL.

View Figures

View References

1	Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, et al: A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 37:551–568.e14. 2020. View Article : Google Scholar : PubMed/NCBI
3	Hertzberg M: R-CHOP in DLBCL: Priming for success. Blood. 139:1121–1122. 2022. View Article : Google Scholar : PubMed/NCBI
4	Wang L and Li LR: R-CHOP resistance in diffuse large B-cell lymphoma: Biological and molecular mechanisms. Chin Med J (Engl). 134:253–260. 2020. View Article : Google Scholar : PubMed/NCBI
5	Goldfinger M and Cooper DL: Refractory DLBCL: Challenges and treatment. Clin Lymphoma Myeloma Leuk. 22:140–148. 2022. View Article : Google Scholar : PubMed/NCBI
6	Liu Y and Barta SK: Diffuse large B-cell lymphoma: 2019 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI
7	Li T, Yu J, Hou M, Zha S, Cheng Q, Zheng Q and Li L: Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis. Pharmacol Res. 187:1065922023. View Article : Google Scholar : PubMed/NCBI
8	He MY and Kridel R: Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 35:2151–2165. 2021. View Article : Google Scholar : PubMed/NCBI
9	Hoy SM: Sintilimab: First global approval. Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
10	Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
11	Liu X and Yi Y: Recent updates on sintilimab in solid tumor immunotherapy. Biomark Res. 8:692020. View Article : Google Scholar : PubMed/NCBI
12	Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study. Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
13	Chen C, Zhang W, Zhou D and Zhang Y: Sintilimab and chidamide for refractory transformed diffuse large B cell lymphoma: A case report and a literature review. Front Oncol. 11:7574032021. View Article : Google Scholar : PubMed/NCBI
14	Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D and Kulangara K: Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 24:392–397. 2016. View Article : Google Scholar : PubMed/NCBI
15	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, . B-cell lymphomas. Version 4.2019. 2019.Retrieved from. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
16	Tanimura A, Nakazato A and Tanaka N: MYD88 signals induce tumour-initiating cell generation through the NF-κB-HIF-1α activation cascade. Sci Rep. 11:39912021. View Article : Google Scholar : PubMed/NCBI
17	Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI
18	Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, et al: MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study. Clin Lymph Myelom Leuk. 22 (Suppl 2):S394–S395. 2022. View Article : Google Scholar
19	Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, et al: Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 127:3026–3034. 2016. View Article : Google Scholar : PubMed/NCBI
20	Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 116:3268–3277. 2010. View Article : Google Scholar : PubMed/NCBI
21	Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW, Orlowski R, et al: PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 133:2279–2290. 2019. View Article : Google Scholar : PubMed/NCBI
22	Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, Qiu L, Qian Z, Zhou S, Gong W, et al: Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer. 10:e0041142022. View Article : Google Scholar : PubMed/NCBI
24	Zhang L, Mai W, Jiang W and Geng Q: Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol. 10:5945582020. View Article : Google Scholar : PubMed/NCBI
25	Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al: Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study. J Clin Oncol. 34:2698–2704. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, et al: Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study. J Clin Oncol. 37:481–489. 2019. View Article : Google Scholar : PubMed/NCBI
27	Gregory GP, Kumar S, Wang D, Mahadevan D, Walker P, Wagner-Johnston N, Escobar C, Bannerji R, Bhutani D, Chang J, et al: Pembrolizumab plus dinaciclib in patients with hematologic malignancies: The phase 1b KEYNOTE-155 study. Blood Adv. 6:1232–1242. 2022. View Article : Google Scholar : PubMed/NCBI
28	Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, et al: Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial. Leukemia. 27:1902–1909. 2013. View Article : Google Scholar : PubMed/NCBI
29	Messal N, Serriari NE, Pastor S, Nunès JA and Olive D: PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol. 48:2214–2219. 2011. View Article : Google Scholar : PubMed/NCBI
30	Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al: PD-L2 expression in human tumors: Relevance to Anti-PD-1 therapy in cancer. Clin Cancer Res. 23:3158–3167. 2017. View Article : Google Scholar : PubMed/NCBI
31	Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, et al: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 109:3879–3884. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lohmann K and Klein C: Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics. 11:699–707. 2014. View Article : Google Scholar : PubMed/NCBI
33	Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann Oncol. 31:1491–1505. 2020. View Article : Google Scholar : PubMed/NCBI
34	Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M and Jamali E: The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract. 230:1537602022. View Article : Google Scholar : PubMed/NCBI
35	Adams E, Sepich-Poore GD, Miller-Montgomery S and Knight R: Using all our genomes: Blood-based liquid biopsies for the early detection of cancer. View (Beijing). 3:202001182022.PubMed/NCBI
36	Huang Y, Du S, Liu J, Huang W, Liu W, Zhang M, Li N, Wang R, Wu J, Chen W, et al: Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints. Proc Natl Acad Sci USA. 119:e21222451192022. View Article : Google Scholar : PubMed/NCBI